Infectious Disease & Sepsis

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine (nejm.org)

Population:

• Study Participants: Adolescent girls and young women in South Africa and Uganda.

• Sample Size: 5338 participants who were initially HIV-negative.

Intervention:

• Primary Intervention: Subcutaneous lenacapavir administered every 26 weeks.

For those who did not witness the start of the HIV pandemic, this was the first report!

And here is the progress made in relation to antiretroviral medications (ART) over the past 40 years or so!

This shows the life cycle of HIV and the different mechanisms of ART medications.